Engligliflozin API

Name	Engligliflozin
Chinese name	恩格列净
Cas Number	915095-94-2
Source	India
Qualifications	USDMF/-/-/-/-

Enpagliflozin was developed by Boehringer Ingelheim. It was first approved for marketing by the European Medicines Agency (EMA) on May 22, 2014, and then approved by the U.S. FDA on August 1, 2014, and in December 2014. On the 26th, it was approved by the Pharmaceuticals and Medical Devices Administration (PMDA) of Japan. This product is a highly selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor, and its hypoglycemic effect does not depend on β cell function and insulin resistance. In addition to having a clear hypoglycemic effect, empagliflozin can also bring additional benefits of weight loss, lower blood pressure, and lower uric acid to patients. It does not affect the production of endogenous glucose in the body during hypoglycemia, and the risk of hypoglycemia is lower. . Enpagliflozin is currently the only SGLT2 inhibitor that has been proven to reduce the risk of cardiovascular death. It has been jointly recommended by more than 60 national guidelines and is widely used worldwide. It holds the top position in the SGLT2 inhibitor drug market with market share. More than 50%. In 2018, the global sales of Boehringer Ingelheim's Enpagliflozin (single drug) were 1.461 billion euros, an increase of 45% compared to 2017.

Hot Tags: engligliflozin api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Valganciclovir Hydrochloride API, Temozolomide API, Perindopril Tert butylamine Salt API, Active Pharmaceutical Ingredient, Gabapentin API, Tavaborol API

• Previous: Bedaquinoline Fumarate API
• Next: Fimasartan Potassium API